Low Level, Carryover Free and Wide Range, LC-MS/MS Method for Quantitation of Semaglutide from Human Plasma

User Benefits

- Method for Semaglutide quantitation from human plasma was developed and validated as per ICH M10 guidelines. - The developed method achieved a low limit of quantification (LLOQ) level and wide dynamic range. - The developed method demonstrates no carryover for the dynamic range covered.

Introduction

Semaglutide is a peptide used as an antidiabetic medication for the treatment of type-2 diabetes. It is also used as an anti-obesity medication for weight loss. Recently, studies have shown that Semaglutide also works on the brain, suggesting its potential utility for various diseases, including Parkinson's disease and Alzheimer's disease. The non-specific adsorption of Semaglutide on column, HPLC flow path and high background noise at low level in complex matrix like human plasma makes quantitation of Semaglutide difficult at low level. To overcome these challenges, we developed an MRM based LC-MS/MS method for quantifying Semaglutide. This method is well- suited for pharmacokinetic studies of Semaglutide because it offers ,low limit of quantification, no carryover and has a wide dynamic range . Shimadzu LCMS-8060NX was used to determine Semaglutide in plasma at low levels.

February 17, 2025 GMT